THE asthma therapeutics market in the Asia-Pacific region is expected to grow from US$4.1 billion last year to about US$6 billion by 2023, according to a new analysis by GBI Research.
The company said the strong growth would be driven by the ageing population in Australia, India, China, Japan and South Korea as well as increases in pollution, a promising product pipeline and the launch of first-in-class molecules - in particular a rise in biologic development in the asthma market.
For more see gbiresearch.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 17